Insider Buying: TherapeuticsMD, Inc. (NASDAQ:TXMD) Major Shareholder Acquires 7,000 Shares of Stock
Insider Buying: TherapeuticsMD, Inc. (NASDAQ:TXMD) Major Shareholder Acquires 7,000 Shares of Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Rating) major shareholder Rubric Capital Management Lp bought 7,000 shares of the company's stock in a transaction on Friday, September 30th. The shares were acquired at an average price of $1,000.00 per share, for a total transaction of $7,000,000.00. Following the completion of the acquisition, the insider now owns 22,000 shares in the company, valued at $22,000,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
納斯達克(股票代碼:TXMD-GET Rating)的大股東Rubric Capital Management LP在9月30日(星期五)的一筆交易中購買了7,000股該公司股票。這些股票是以每股1,000.00美元的平均價格收購的,總交易額為7,000,000.00美元。收購完成後,這位內部人士現在擁有該公司22,000股,價值22,000,000美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在美國證券交易委員會網站。持有公司10%或以上股份的大股東必須披露他們與美國證券交易委員會的交易。
Rubric Capital Management Lp also recently made the following trade(s):
Rbric Capital Management LP最近還進行了以下交易:
- On Friday, July 29th, Rubric Capital Management Lp acquired 580,000 shares of TherapeuticsMD stock. The shares were acquired at an average price of $25.86 per share, for a total transaction of $14,998,800.00.
- On Monday, July 18th, Rubric Capital Management Lp acquired 17,688 shares of TherapeuticsMD stock. The shares were acquired at an average cost of $6.03 per share, for a total transaction of $106,658.64.
- On Friday, July 15th, Rubric Capital Management Lp bought 64,892 shares of TherapeuticsMD stock. The shares were bought at an average price of $5.56 per share, with a total value of $360,799.52.
- 7月29日星期五,Rubric Capital Management LP收購了TreateuticsMD股票58萬股。這些股票是以每股25.86美元的平均價格收購的,總交易額為14,998,800.00美元。
- 7月18日,星期一,Rubric Capital Management LP收購了TreateuticsMD股票17,688股。這些股票是以每股6.03美元的平均成本收購的,總交易額為106,658.64美元。
- 7月15日,星期五,Rubric Capital Management LP購買了64,892股TreateuticsMD股票。這些股票是以每股5.56美元的平均價格購買的,總價值為360,799.52美元。
TherapeuticsMD Stock Down 7.5 %
TreateuticsMD股價下跌7.5%
NASDAQ:TXMD traded down $0.50 during mid-day trading on Monday, reaching $6.14. 127,905 shares of the stock were exchanged, compared to its average volume of 614,731. The company has a 50 day simple moving average of $8.73 and a 200-day simple moving average of $8.55. TherapeuticsMD, Inc. has a 1 year low of $1.99 and a 1 year high of $40.90. The stock has a market capitalization of $57.87 million, a P/E ratio of -1.62 and a beta of 1.54.
納斯達克:週一午盤,TXMD下跌0.5美元,至6.14美元。該股成交量為127,905股,而平均成交量為614,731股。該公司的50日簡單移動均線切入位在8.73美元,200日簡單移動均線切入位在8.55美元。TreateuticsMD公司的一年低點為1.99美元,一年高位為40.90美元。該股市值為5,787萬美元,市盈率為-1.62,貝塔係數為1.54。
Institutional Trading of TherapeuticsMD
治療藥物的制度性交易MD
A number of large investors have recently modified their holdings of TXMD. Point72 Hong Kong Ltd grew its position in TherapeuticsMD by 236.8% in the fourth quarter. Point72 Hong Kong Ltd now owns 123,517 shares of the company's stock worth $44,000 after buying an additional 86,845 shares during the last quarter. Principal Financial Group Inc. grew its position in TherapeuticsMD by 6.3% during the 1st quarter. Principal Financial Group Inc. now owns 123,319 shares of the company's stock worth $47,000 after purchasing an additional 7,263 shares in the last quarter. McDonald Partners LLC purchased a new position in TherapeuticsMD during the 1st quarter worth approximately $49,000. GSA Capital Partners LLP purchased a new position in TherapeuticsMD during the 1st quarter worth approximately $79,000. Finally, JPMorgan Chase & Co. grew its position in TherapeuticsMD by 22.6% during the 1st quarter. JPMorgan Chase & Co. now owns 255,249 shares of the company's stock worth $97,000 after purchasing an additional 46,974 shares in the last quarter.
一些大型投資者最近調整了對TXMD的持股。Point72 Hong Kong Ltd於第四季在TreateuticsMD的持倉增加236.8%。Point72 Hong Kong Ltd目前持有123,517股該公司股票,價值44,000美元,上一季度又購買了86,845股。第一季度,信安金融集團在TreateuticsMD的地位增長了6.3%。在上個季度又購買了7,263股後,信安金融集團現在持有123,319股該公司股票,價值47,000美元。McDonald Partners LLC在第一季度購買了TreateuticsMD的一個新頭寸,價值約4.9萬美元。GSA Capital Partners LLP在第一季度購買了TreateuticsMD的一個新頭寸,價值約7.9萬美元。最後,摩根大通第一季度在TreateuticsMD的倉位增加了22.6%。摩根大通在上個季度增持了46,974股,目前持有255,249股該公司股票,價值97,000美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
TXMD has been the subject of several recent analyst reports. Cantor Fitzgerald reiterated a "neutral" rating on shares of TherapeuticsMD in a research note on Wednesday, July 13th. HC Wainwright lowered TherapeuticsMD from a "buy" rating to a "neutral" rating in a research note on Tuesday, June 7th. Finally, StockNews.com raised TherapeuticsMD from a "sell" rating to a "hold" rating in a research note on Tuesday, August 16th.
TXMD一直是最近幾份分析師報告的主題。坎託·菲茨傑拉德在7月13日星期三的一份研究報告中重申了對TreateuticsMD股票的“中性”評級。在6月7日星期二的一份研究報告中,HC Wainwright將TreateuticsMD的評級從“買入”下調至“中性”。最後,StockNews.com在8月16日星期二的一份研究報告中將TreateuticsMD的評級從“賣出”上調至“持有”。
About TherapeuticsMD
關於TreateticsMD
(Get Rating)
(獲取評級)
TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
TreateuticsMD,Inc.在美國是一家女性保健公司。該公司提供用於治療中到重度性交困難的IMVEXXY;BIJUVA,一種生物相同的激素療法,結合17?雌二醇和孕酮,用於治療中到重度的血管舒縮症狀;以及ANNOVERA,一種環形避孕陰道系統。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on TherapeuticsMD (TXMD)
- Near-Term Headwinds Send Nike To The Bargain Basement
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- Is the Bond Market Signaling a Market Bottom?
- 免費獲取StockNews.com關於治療藥物的研究報告(TXMD)
- 近期的逆風將耐克送到了廉價地下室
- 阿徹·丹尼爾斯·米德蘭:49年增長的紅利英雄
- 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎?
- 麥格納國際是您的汽車和電動汽車一站式庫存
- 債券市場是否發出了市場觸底的信號?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
接受治療新聞和評級MD日報-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收對TreateuticsMD和相關公司的最新新聞和分析師評級的每日簡要摘要。